Intravenous Immunoglobulin Market Size, Growth | Forecast 2028

The intravenous immunoglobulin market was valued at US$ 11,206.54 million in 2021 and is likely to reach to a value of US$ 18,672.55 million by 2028; it is estimated to grow at a CAGR of 7.6% from 2022 to 2028.

Immunoglobulins are the antibodies produced naturally by the body’s immune system, which help fight infection and disease. The deficiency of immunoglobulin requires the external administration of immunoglobulin and is known as immunoglobulin replacement therapy (IgRT). IgRT can be given intravenously and subcutaneously. Intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg) are selected based on the indication and severity. IVIg is manufactured from human plasma. It contains antibodies and is used to treat a growing number of immunologic, hematologic, and neurologic illnesses.

Strategic Insights

The intravenous immunoglobulin market is segmented into type, application, distribution channel, end user, and geography. By geography, the market is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. This report offers insights and in-depth analysis of the market, emphasizing parameters, such as market trends, market dynamics, and the competitive analysis of the globally leading market players.     

Lucrative Regions for Intravenous Immunoglobulin Market

Get more information on this report : Request Free Sample PDF

Market Insights

Rising prevalence of immunodeficiency diseases and increasing geriatric population is driving the intravenous immunoglobulin market.

According to the National Institute of Allergy and Infectious Diseases (NIAID), over 200 different types of primary immune deficiency diseases (PIDDs) affect about 500,000 people in the US. The rare genetic diseases can be chronic, weak, and expensive. Immune Thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by abnormally low levels of platelets; a situation referred to as thrombocytopenia. According to the Rare Diseases Organization, around 200,000 ITP cases are recorded worldwide annually. Further, according to the United Nations Population Division, World Population Prospects 2019, Asian and European countries have some of the world’s oldest populations aged 65 and over. Japan is at the top with 28%, followed by Italy at 23%. Further, Finland, Portugal, and Greece are among the top five countries with an aged population under 22%. Many of the patients treated with IVIG are above the age of 60 years. With aging, the ability to produce T-cells to fight diseases gets significantly reduced. Thus, an older person’s body is easily prone to several infections and diseases, which increases the demand for immune therapies that involve the use of IVIg. Thus, the rise in immunodeficiency diseases and increasing geriatric population across the globe is bolstering the intravenous immunoglobulin market. 

Type-Based Insights

Based on the type, the intravenous immunoglobulin market is segmented into IgG, IgM, IgA, IgE, and IgD. The IgG type immunoglobulin segment held the largest market share in 2021. However, the handheld segment is anticipated to register the highest CAGR during the forecast period owing to its wide application of IgG in treating several categories of disorders.

Intravenous Immunoglobulin Market, by Type – 2021 and 2028

Get more information on this report : Request Free Sample PDF

Application-Based Insights

Based on application, the intravenous immunoglobulin market is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, inflammatory myopathies, specific antibody deficiency, Guillain-Barre syndrome, and others. In 2021, the immunodeficiency diseases segment held the market's largest share. Moreover, the same segment is expected to witness growth in its demand at the fastest CAGR from 2022 to 2028 due to the rising prevalence of immunodeficiency diseases and increasing FDA approvals for IVIg products to treat immunodeficiency.

Distribution Channel-Based Insights

Based on distribution channel, the intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. In 2021, the hospital pharmacy segment held the largest share of the market. Further, the retail pharmacy segment is expected to witness growth in its demand at the fastest CAGR from 2022 to 2028, owing to the expansions of retail pharmacies and the shift of consumer behavior towards organized retail pharmacies that offer high-quality drugs and medicines.

End User-Based Insights

Based on end user, the intravenous immunoglobulin market is segmented into hospitals, specialty clinics, and others. In 2021, the hospitals segment held the largest share of the market. Further, the specialty clinics segment is expected to witness growth in demand at the fastest CAGR from 2022 to 2028, owing to the advances in specialty clinics for offering quick and accurate IgRT to patients.

Organic developments such as product approvals are highly adopted strategies by the global intravenous immunoglobulin market players. A few of the recent key market developments are listed below: 

• In March 2022, ADMA Biologics, Inc. announced the United States Food and Drug Administration’s (FDA) approval to extend the expiration dating from 24 to 36 months for both its ASCENIV and BIVIGAM immune globulin (“IG”) drug product stored at 2-8°C. The expiration date extension applies to all existing ASCENIV and BIVIGAM lots currently in the commercial supply chain as well as to future production of ASCENIV and BIVIGAM in all vial sizes, production scales as well as internal and external fill-finished drug product.
• In June 2021, Octapharma announced that octagam 10%, a human plasma-derived intravenous immunoglobulin (IVIg), has recently been granted approval in the European Union (EU) as an immunomodulatory therapy for adults with dermatomyositis. Following the EU approval, octagam 10% received national approval in Germany on May 11, 2021, with approval in other European member states expected soon.
• In April 2021, ADMA Biologics, Inc. announced that the U.S. Food and Drug Administration (“FDA”) approved the Company’s expanded manufacturing process, enabling fractionation and purification of a 4,400-liter plasma pool for the manufacture of Intravenous Immune Globulin (“IVIG”).
• In February 2020, CSL Behring announced that the U.S. Food and Drug Administration (FDA) granted Privigen (Immune Globulin Intravenous (Human), 10% Liquid) orphan-drug designation as an investigational therapy in the treatment of Systemic Sclerosis (SSc).

Such developments by market players are driving the intravenous immunoglobulin market.

Intravenous Immunoglobulin – Market Segmentation

The global intravenous immunoglobulin market is segmented into type, application, distribution channel, end user, and geography. Based on type, the market is segmented into IgG, IgM, IgA, IgE, and IgD). By Application, the market is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, inflammatory myopathies, specific antibody deficiency, Guillain-Barre syndrome, and others. Based on distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and others. By End User, the market is segmented into hospitals, specialty clinics, and others. By geography, the market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America.  

Company Profiles

• Takeda Pharmaceutical Company Limited
• Grifols, S.A.
• Pfizer Inc.
• ADMA Biologics Inc.
• Bio Products Laboratory Ltd.
• Shanghai RAAS
• Octapharma AG
• Kedrion S.p.A
• CSL Behring (CSL Limited)
• Prothya Biosolutions B.V.